{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T21:03:19Z","timestamp":1789333399506,"version":"build-2803163510"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011096","name":"Jazz Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011096","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007737","name":"St. Jude Children's Research Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007737","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.clml.2026.08.009","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T16:10:45Z","timestamp":1787155845000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The 21st International ``Ponte di Legno'' Childhood Acute Lymphoblastic Leukemia Workshop Report: Progress and Emerging Opportunities"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3495-7578","authenticated-orcid":false,"given":"Sarah","family":"Elitzur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaoyang","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats M.","family":"Heyman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5492-3957","authenticated-orcid":false,"given":"Stephen P.","family":"Hunger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroto","family":"Inaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8113-8180","authenticated-orcid":false,"given":"Seth E.","family":"Karol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mignon L.","family":"Loh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Manabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Pieters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0303-5658","authenticated-orcid":false,"given":"Ching-Hon","family":"Pui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4828-3893","authenticated-orcid":false,"given":"Carmelo","family":"Rizzari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis B.","family":"Silverman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7373-8987","authenticated-orcid":false,"given":"David T.","family":"Teachey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Schrappe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.clml.2026.08.009_bib0001","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJM200004063421402","article-title":"Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"342","author":"Aric\u00f2","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2026.08.009_bib0002","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(02)08782-2","article-title":"Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region","volume":"359","author":"Arico\u00b4","year":"2002","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.clml.2026.08.009_bib0003","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/sj.leu.2403695","article-title":"No prognostic effect of additional chromosomal abnormalities in children with acute lymphoblastic leukemia and 11q23 abnormalities","volume":"19","author":"Moorman","year":"2005","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.clml.2026.08.009_bib0004","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/leu.2013.317","article-title":"An international study of intrachromosomal amplification of chromosome 21 (iAMP21): cytogenetic characterization and outcome","volume":"28","author":"Harrison","year":"2014","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.clml.2026.08.009_bib0005","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1182\/blood-2013-06-509463","article-title":"Acute lymphoblastic leukemia in children with down syndrome: a retrospective analysis from the Ponte di Legno study group","volume":"123","author":"Buitenkamp","year":"2014","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clml.2026.08.009_bib0006","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1200\/JCO.18.00822","article-title":"Outcome of children with hypodiploid acute lymphoblastic leukemia: a retrospective multinational study","volume":"37","author":"Pui","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2026.08.009_bib0007","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/S2352-3026(20)30353-7","article-title":"Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era: a multicentre, retrospective, cohort study","volume":"8","author":"den Boer","year":"2021","journal-title":"Lancet Haematol"},{"issue":"11","key":"10.1016\/j.clml.2026.08.009_bib0008","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1038\/s41375-021-01199-0","article-title":"Clinical characteristics and outcomes of B-ALL with ZNF384 rearrangements: a retrospective analysis by the Ponte di Legno Childhood ALL Working Group","volume":"35","author":"Hirabayashi","year":"2021","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.clml.2026.08.009_bib0009","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41375-022-01737-4","article-title":"Clinical characteristics and outcomes of B-cell precursor ALL with MEF2D rearrangements: a retrospective study by the Ponte di Legno Childhood ALL Working Group","volume":"37","author":"Ohki","year":"2023","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.clml.2026.08.009_bib0010","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1200\/JCO.22.01297","article-title":"Outcomes of childhood noninfant acute lymphoblastic leukemia with 11q23\/KMT2A rearrangements in a modern therapy era: a retrospective international study","volume":"41","author":"Attarbaschi","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.08.009_bib0011","doi-asserted-by":"crossref","unstructured":"Kimura S, Park CS, Montefiori LE, et al. Biologic and clinical analysis of childhood Gamma Delta T-ALL identifies LMO2\/STAG2 rearrangements as extremely high risk. Cancer Discov. 2024;14(10):1838-1859. doi: 10.1158\/2159-8290.CD-23-1452.","DOI":"10.1158\/2159-8290.CD-23-1452"},{"issue":"15","key":"10.1016\/j.clml.2026.08.009_bib0012","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1056\/NEJMoa1110169","article-title":"Outcomes after induction failure in childhood acute lymphoblastic leukemia","volume":"366","author":"Schrappe","year":"2012","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.clml.2026.08.009_bib0013","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1200\/JCO.2012.47.0500","article-title":"Second malignant neoplasms after treatment of childhood acute lymphoblastic leukemia","volume":"31","author":"Schmiegelow","year":"2013","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.clml.2026.08.009_bib0014","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1182\/blood.2022016975","article-title":"EBV-driven lymphoid neoplasms associated with pediatric ALL maintenance therapy","volume":"141","author":"Elitzur","year":"2023","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2026.08.009_bib0015","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/S1470-2045(17)30424-2","article-title":"Asparaginase-associated pancreatitis in childhood acute lymphoblastic leukaemia: an observational Ponte di Legno Toxicity Working Group study","volume":"18","author":"Wolthers","year":"2017","journal-title":"Lancet Oncol"},{"issue":"7727","key":"10.1016\/j.clml.2026.08.009_bib0016","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/s41586-018-0436-0","article-title":"The genetic basis and cell of origin of mixed phenotype acute leukaemia","volume":"562","author":"Alexander","year":"2018","journal-title":"Nature"},{"issue":"32","key":"10.1016\/j.clml.2026.08.009_bib0017","doi-asserted-by":"crossref","first-page":"5025","DOI":"10.1200\/JCO.23.00088","article-title":"Outcome for children and young adults with T-cell ALL and induction failure in contemporary trials","volume":"41","author":"Raetz","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clml.2026.08.009_bib0018","doi-asserted-by":"crossref","first-page":"e231","DOI":"10.1016\/S1470-2045(16)30035-3","article-title":"Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus","volume":"17","author":"Schmiegelow","year":"2016","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.clml.2026.08.009_bib0019","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1182\/blood.2021012328","article-title":"Remission, treatment failure, and relapse in pediatric ALL: an international consensus of the Ponte-di-Legno Consortium","volume":"139","author":"Buchmann","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.08.009_bib0020","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/sj.leu.2402872","article-title":"Ponte di Legno\u2019 working group \u2013 report on the fifth international childhood acute lymphoblastic leukemia workshop: vienna, Austria, 29 April \u20131 May 2002","volume":"17","author":"Gadner","year":"2003","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.clml.2026.08.009_bib0021","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1038\/s41375-022-01668-0","article-title":"Minimal residual disease in BCR::ABL1-positive acute lymphoblastic leukemia: different significance in typical ALL and in CML-like disease","volume":"36","author":"Zuna","year":"2022","journal-title":"Leukemia"},{"issue":"20","key":"10.1016\/j.clml.2026.08.009_bib0022","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1182\/blood-2016-11-749978","article-title":"Monitoring of childhood ALL using BCR-ABL1 genomic breakpoints identifies a subgroup with CML-like biology","volume":"129","author":"Hovorkova","year":"2017","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2026.08.009_bib0023","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1182\/blood-2025-551","volume":"146","author":"Maroun","year":"2025","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2026.08.009_bib0024","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1038\/s43018-025-00987-2","article-title":"Multipotent lineage potential in B cell acute lymphoblastic leukemia is associated with distinct cellular origins and clinical features","volume":"6","author":"Iacobucci","year":"2025","journal-title":"Nat Cancer"},{"issue":"6","key":"10.1016\/j.clml.2026.08.009_bib0025","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.3324\/haematol.2024.286111","article-title":"Update on long-term outcomes of a cohort of patients with TCF3::HLF-positive acute lymphoblastic leukemia treated with blinatumomab and stem cell transplantation","volume":"110","author":"Zeckanovic","year":"2025","journal-title":"Haematologica"},{"issue":"8027","key":"10.1016\/j.clml.2026.08.009_bib0026","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1038\/s41586-024-07807-0","article-title":"The genomic basis of childhood T-lineage acute lymphoblastic leukaemia","volume":"632","author":"P\u00f6l\u00f6nen","year":"2024","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.clml.2026.08.009_bib0027","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s43018-024-00863-5","article-title":"A multiomic atlas identifies a treatment-resistant, bone marrow progenitor-like cell population in T cell acute lymphoblastic leukemia","volume":"6","author":"Xu","year":"2025","journal-title":"Nat Cancer"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2026.08.009_bib0028","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1182\/blood-2025-761","article-title":"Clinical characteristics and outcomes of children with T-cell acute lymphoblastic leukemia harboring ABL-class fusions: a report from the Ponte di Legno Consortium [oral abstract]","volume":"146","author":"Tran","year":"2025","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.clml.2026.08.009_bib0029","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1056\/NEJMoa2214171","article-title":"Blinatumomab added to chemotherapy in infant lymphoblastic leukemia","volume":"388","author":"Van der Sluis","year":"2023","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.clml.2026.08.009_bib0030","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1200\/JCO-25-01806","article-title":"Sustained benefit of blinatumomab in infants with KMT2A-rearranged ALL: long-term outcomes, toxicity, and pharmacokinetics","volume":"44","author":"Vieira Martins","year":"2026","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.clml.2026.08.009_bib0031","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1038\/s41375-021-01333-y","article-title":"Favorable outcome of NUTM1-rearranged infant and pediatric B cell precursor acute lymphoblastic leukemia in a collaborative international study","volume":"35","author":"Boer","year":"2021","journal-title":"Leukemia"},{"issue":"36","key":"10.1016\/j.clml.2026.08.009_bib0032","doi-asserted-by":"crossref","first-page":"5579","DOI":"10.1200\/JCO.23.01286","article-title":"Advancing diagnostics and therapy to reach universal cure in childhood ALL","volume":"41","author":"Pieters","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clml.2026.08.009_bib0033","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1038\/s41591-023-02339-y","article-title":"A joint international consensus statement for measuring quality of survival for patients with childhood cancer","volume":"29","author":"van Kalsbeek","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2026.08.009_bib0034","series-title":"Replacement of high dose combination chemotherapy with blinatumomab in newly diagnosed pediatric high-risk B-cell ALL improves efficacy and safety in the randomized phase 3 AIEOP-BFM ALL 2017 trial [abstract S103]. HemaSphere","author":"Schrappe","year":"2026"},{"issue":"8","key":"10.1016\/j.clml.2026.08.009_bib0035","doi-asserted-by":"crossref","DOI":"10.1002\/1545-5017.70405","article-title":"Heterogeneity in the global practice of central nervous system staging in pediatric acute lymphoblastic leukemia","volume":"73","author":"Alm\u00e1si","year":"2026","journal-title":"Pediatr Blood Cancer"},{"issue":"8","key":"10.1016\/j.clml.2026.08.009_bib0036","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard care for relapsed or refractory acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.clml.2026.08.009_bib0037","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1002\/cncr.35505","article-title":"Inotuzumab ozogamicin in adult acute lymphoblastic leukemia: development, current status, and future directions","volume":"130","author":"Kantarjian","year":"2024","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.clml.2026.08.009_bib0038","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1200\/JCO.21.01693","article-title":"Phase II trial of inotuzumab ozogamicin in children and adolescents with relapsed or refractory B-cell acute lymphoblastic leukemia: children's Oncology Group protocol AALL1621","volume":"40","author":"O'Brien","year":"2022","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.clml.2026.08.009_bib0039","doi-asserted-by":"crossref","first-page":"e449","DOI":"10.1016\/S2352-3026(26)00104-3","article-title":"Inotuzumab ozogamicin in paediatric very high risk first B-cell acute lymphoblastic leukaemia relapse (ITCC-059): a multicentre, single-arm, phase 2 trial","volume":"13","author":"Peccatori","year":"2026","journal-title":"Lancet Haematol"},{"issue":"9","key":"10.1016\/j.clml.2026.08.009_bib0040","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2411680","article-title":"Blinatumomab in standard-risk B-cell acute lymphoblastic leukemia in children","volume":"392","author":"Gupta","year":"2025","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clml.2026.08.009_bib0041","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa2312948","article-title":"Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults","volume":"391","author":"Litzow","year":"2024","journal-title":"N Engl J Med"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026002703?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026002703?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T20:04:13Z","timestamp":1789329853000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026002703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":41,"alternative-id":["S2152265026002703"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.08.009","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The 21st International ``Ponte di Legno'' Childhood Acute Lymphoblastic Leukemia Workshop Report: Progress and Emerging Opportunities","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}